Is Cagrilintide Safe? What the Evidence Says So Far

What Is Cagrilintide and Where Does It Stand Legally?

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. Amylin is a hormone secreted alongside insulin from pancreatic beta cells. It slows gastric emptying, reduces glucagon release after meals, and signals satiety to the brain. Cagrilintide is designed to mimic those effects with a half-life long enough for once-weekly dosing, which is why researchers have studied it both alone and in combination with semaglutide in a fixed-ratio co-formulation called CagriSema.

As of mid-2025, cagrilintide has not received FDA approval as a standalone drug. The branded pharmaceutical products Wegovy and Ozempic contain semaglutide, and Mounjaro and Zepbound contain tirzepatide. None of those approvals extend to cagrilintide or to CagriSema, which remains in Phase 3 trials. Research-chemical versions sold online are not approved, not regulated for purity or potency, and carry risks that clinical-trial formulations do not.

This distinction matters for safety. Every side effect figure cited in this article comes from controlled trials using pharmaceutical-grade material under medical supervision. Purity, sterility, and accurate dosing in unregulated sources cannot be assumed, which adds a separate layer of risk that the published studies do not capture.

What Do Clinical Trials Actually Show About Side Effects?

The most detailed early safety data comes from a Phase 2 trial published in The Lancet in 2021 (Enebo et al., PMID 33838736). That trial enrolled 706 adults with obesity across multiple dose groups and ran for 26 weeks. The most common adverse events were gastrointestinal: nausea affected roughly 33 to 47 percent of participants depending on dose, vomiting affected 16 to 28 percent, and diarrhea and constipation were also reported. These rates are broadly consistent with other amylin-based and GLP-1-based compounds.

Injection-site reactions, including redness, swelling, and discomfort, were reported more frequently with cagrilintide than with placebo in that same trial. Most were described as mild to moderate. Serious adverse events occurred in a small percentage of participants across groups, and the trial did not identify a new or unexpected safety signal beyond what the gastrointestinal profile would suggest.

The REDEFINE 1 Phase 3 trial, which studies CagriSema (cagrilintide combined with semaglutide), has been ongoing and results have been reported in stages through 2024 and 2025. Preliminary data presented at medical conferences suggest the gastrointestinal side effect pattern persists in the combination, with nausea and vomiting remaining the most frequently cited complaints. Full peer-reviewed publication of complete Phase 3 safety data was not yet available at the time this article was written, which means the picture is still forming.

Known Red Flags and Signals Worth Watching

Hypoglycemia is a theoretical concern with any compound that influences insulin and glucagon dynamics. In the Phase 2 Lancet trial, hypoglycemia events were reported but were generally low in frequency among participants without type 2 diabetes. The risk profile may differ in people who also take insulin or other glucose-lowering medications, and that interaction has not been fully characterized in long-term data.

Heart rate elevation has been observed with several GLP-1 receptor agonists, and researchers have monitored for it in cagrilintide trials as well. The Phase 2 data showed modest increases in resting heart rate in some dose groups. The clinical significance of this finding over years of use is not yet established, and it is one of the signals that ongoing Phase 3 monitoring is designed to track.

Pancreatitis is a labeled warning for approved amylin and GLP-1 class drugs. No confirmed cases of pancreatitis were reported in the Phase 2 cagrilintide trial, but the sample size and duration were not large enough to rule out a rare association. Anyone with a personal or family history of pancreatitis, gallbladder disease, or medullary thyroid carcinoma should be aware that these are established concerns for the broader drug class, even if cagrilintide-specific data on these outcomes is thin.

Who Should Be Especially Cautious?

Pregnant and breastfeeding individuals should not use investigational compounds. There is no human safety data for cagrilintide in pregnancy, and animal reproductive toxicology studies are not a substitute for that gap. The same caution applies to anyone planning to become pregnant in the near term.

People with a personal or family history of multiple endocrine neoplasia type 2 (MEN 2) or medullary thyroid carcinoma face a class-level concern. Approved semaglutide products carry a boxed warning about thyroid C-cell tumors based on rodent studies. Whether cagrilintide carries the same signal independently is not established, but the combination product CagriSema would inherit semaglutide's warning.

Individuals with kidney disease, liver disease, or a history of eating disorders represent populations where the gastrointestinal burden of this compound could be more consequential. Persistent nausea and vomiting can worsen dehydration and electrolyte imbalances in people whose kidneys or livers are already under stress. These groups were either excluded from or underrepresented in early trials, so the safety data does not generalize well to them.

Children and adolescents have not been studied in cagrilintide trials. The compound should be considered entirely uncharacterized in pediatric populations.

What Remains Unknown

Long-term cardiovascular outcomes are the biggest open question. The approved GLP-1 drugs semaglutide and liraglutide have dedicated cardiovascular outcomes trials with thousands of participants followed for years. Cagrilintide does not yet have that data. The REDEFINE program is designed to generate some of it, but results are not complete.

The safety of stopping cagrilintide after extended use is also not well described. With approved GLP-1 drugs, weight regain after discontinuation is well documented. Whether stopping cagrilintide or CagriSema carries additional physiological consequences, such as rebound appetite changes or hormonal shifts, has not been studied in a controlled way.

Drug interactions are another gap. Cagrilintide slows gastric emptying, which can affect the absorption timing of oral medications. This is a known issue with the GLP-1 drug class, but cagrilintide-specific interaction data is sparse. Anyone taking oral medications with narrow therapeutic windows, such as thyroid hormone replacements or certain anticoagulants, should factor this into any conversation with their prescribing physician.